Inhibition of miR-155 Protects Against LPS-induced Cardiac Dysfunction and Apoptosis in Mice

Area of Science:

• Cardiology
• Molecular Biology
• Intensive Care Medicine

Background:

• Sepsis-induced myocardial dysfunction is a leading cause of death in ICUs.
• Dysregulated microRNA-155 (miR-155) is linked to cardiovascular diseases and induced by lipopolysaccharide (LPS).
• The specific role of miR-155 in LPS-induced cardiac dysfunction remains unclear.

Purpose of the Study:

• To investigate the role of miR-155 in lipopolysaccharide (LPS)-induced cardiac dysfunction.
• To explore the therapeutic potential of miR-155 inhibition in sepsis.
• To assess plasma miR-155 as a potential biomarker for septic cardiac dysfunction.

Main Methods:

• Septic cardiac dysfunction induced in mice via LPS injection.
• miR-155 levels assessed in cardiac tissue and plasma.
• Cardiac function evaluated using echocardiography; apoptosis assessed via TUNEL assay and Western blot.
• Pea15a identified as a miR-155 target gene using luciferase reporter assays, qPCR, and Western blot.

Main Results:

• LPS challenge significantly increased miR-155 expression in mouse hearts.
• Pharmacological inhibition of miR-155 improved cardiac function and suppressed apoptosis.
• Overexpression of miR-155 exacerbated cardiac dysfunction and apoptosis.
• Pea15a was confirmed as a direct target of miR-155, mediating cardiomyocyte apoptosis.
• Plasma miR-155 was upregulated in septic patients with cardiac dysfunction compared to those without.

Conclusions:

• miR-155 plays a critical role in mediating LPS-induced cardiac dysfunction and apoptosis.
• Inhibition of miR-155 offers a promising therapeutic strategy for septic myocardial dysfunction.
• Plasma miR-155 shows potential as a diagnostic biomarker for identifying sepsis patients at risk of cardiac dysfunction.